The survival analysis indicated breast cancer patients with high expression of ZNF662 had a better survival probability (Fig. 1E), while hyper-methylation of ZNF662 promoter might contribute to a worse prognosis (Fig. 1F). Here, ZNF662 is linked to breast cancer.